Abstract
In Denmark, the use of clozapine has increased markedly (15–25% per year) since 1983, when the drug was relaunched — after its withdrawal in 1975. Several factors have contributed to this development: 1) the interesting pharmacology of clozapine, especially the atypical influence on dopamine transmission, including a relatively high D-1/D-2 receptor affinity ratio, 2) the potent anti-anxiety and anti-psychotic effect in severe and otherwise therapy-resistent psychotic patients, and 3) the lack of extrapyramidal side effects. A special monitoring form (for registration of total and differential leucocyte counts, ECG, body weight, drugs, doses and reason for possible withdrawal of the clozapine) is used in most Danish psychiatric institutions. This form secures the regular control of vital parameters and serves as an instrument for surveys of the use of clozapine in Denmark. Also, more selective studies are being carried out, e.g., on the effect of clozapine monotherapy versus combined therapy, and on the influence of clozapine on cardiovascular functions, including left ventricular output (echocardiography).
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andersen PH (1988) Comparison of the pharmacological characteristics of 3H-raclopride and 3H-SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113–120
Beier J, Haastrup S (1985) EKG-forandringer udviklet under behandling med klozapin. Ugeskr Laeger 147:619–620
Bürki HR, Ruch W, Asper H, Baggiolini M, Stille G (1973) Pharmakologische und neurochemische Wirkungen von Clozapin: neue Gesichtspunkte in der medikamentösen Behandlung der Schizophrenie. Schweiz Med Wochenschr 103:1716–1720
Farde L, Wiesel F-A, Nordström A-L, Sedvall G (1988) Pet examination of human D1- and D2-dopamine receptor characteristics. Abstracts of the XVIth C.I.N.P. Congress Munich 15–19 August 1988. Psychopharmacology [Suppl] 96:79
Gerlach J, Koppelhus P, Helweg E, Monrad A (1974) Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia. Acta Psychiatr Scand 50:410–424
Gerlach J, Thorsen K, Fog R (1975) Extrapyramidal reactions and amine metabolites in cerebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacologia 40:341–350
Hyttel J (1974) Effect of neuroleptics on the disappearance rate of 3H-labelled catecholamines formed from 14C-tyramine mouse brain. J Pharm Pharmacol 26:588–596
Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45:789–796
Leestma JE, Koenig KL (1968) Sudden death and phenothiazines. Arch Gen Psychiatry 18:137–148
Marder SR, Van Putten T (1988) Who should receive clozapine? Arch Gen Psychiatry 45:865–867
Povlsen UJ, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine. Acta Psychiatr Scand 71:176–185
Sedvall G, Bjerkenstedt L, Lindström L, Wode-Helgodt B (1978) Clinical assessment of dopamine receptor blockade. Life Sci 23:425–430
Tamminga CA, Gerlach J (1987) New neuroleptics and experimental antipsychotics in schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 1129–1140
Vesterby A, Pedersen JH, Kæmpe B, Thomsen NJ (1980) Pludselig død under behandling med klozapin. Ugeskr Laeger 142:170–171
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gerlach, J., Jørgensen, E.O. & Peacock, I. Long-term experience with clozapine in Denmark: research and clinical practice. Psychopharmacology 99 (Suppl 1), S92–S96 (1989). https://doi.org/10.1007/BF00442569
Issue Date:
DOI: https://doi.org/10.1007/BF00442569